Executive Summary

ChemoMetec A/S is a Danish-domiciled life sciences tools company that has established a highly defensible and profitable leadership position in the niche market of automated cell counting. The company’s success is built upon a classic and exceptionally well-executed “razor-and-blade” business model, where the initial sale of its proprietary instruments creates a long-term, high-margin recurring revenue stream from the sale of essential, single-use consumables. This model provides both scalability and a significant degree of revenue stability.

The company’s competitive advantage is multifaceted and robust. It is rooted in its user-friendly, accurate, and reliable image cytometry technology, which has become a de facto standard in specific, demanding applications. The most significant competitive moat, however, is the company’s entrenched position within the highly regulated Good Manufacturing Practice (GMP) workflows of its customers, particularly in the burgeoning cell and gene therapy (CGT) sector. Once a ChemoMetec instrument is validated and written into a customer’s regulatory-approved manufacturing process, the costs and risks associated with switching to a competitor become prohibitively high, creating a powerful customer lock-in effect.

The period between 2022 and 2024 served as a critical test of the business model’s resilience. A cyclical downturn in biotech funding—a “biotech winter”—led to a sharp contraction in customer capital expenditure, causing a significant decline in ChemoMetec’s instrument sales in fiscal year 2023/24. However, the stability of the recurring consumable and service revenue, generated from the large installed base of instruments, provided a crucial buffer that mitigated a more severe decline. The subsequent sharp recovery in instrument sales in the latter half of 2024 demonstrated the model’s powerful operating leverage and its sensitivity to improving market conditions.

Strategically, ChemoMetec is at a pivotal juncture. The recent launch of its next-generation XcytoMatic® instrument platform is set to drive the next wave of growth and further penetrate high-throughput applications. More transformatively, the October 2024 acquisition of Ovizio Imaging Systems moves the company into the highly strategic market for in-line Process Analytical Technology (PAT), allowing for real-time cell analysis directly within a customer’s bioreactor. This move significantly expands the company’s addressable market and deepens its integration into the core biomanufacturing workflow.

Financially, ChemoMetec exhibits an exceptional profile characterized by industry-leading profitability margins, high returns on invested capital, strong free cash flow generation, and a pristine balance sheet with a substantial net cash position. This financial strength provides both operational resilience and strategic flexibility. This combination of high quality and strong growth prospects is reflected in the company’s stock, which consistently trades at a significant premium to its life sciences tools peers. The central analytical question for investors is whether the company’s superior quality, defensible market position, and clear growth runway justify this premium valuation, particularly given the inherent cyclicality tied to the biotech funding environment.

I. Company Profile: A Niche Leader in Cell Counting

1.1 Core Business Operations

Founded in 1997 and headquartered in Allerød, Denmark, ChemoMetec A/S specializes in the development, manufacturing, and global distribution of high-precision analytical instruments for cell counting and analysis.¹ The company has carved out a distinct and valuable niche within the broader life sciences instrumentation market by focusing on providing solutions that are accurate, reliable, and exceptionally easy to use.⁴

The technological foundation of ChemoMetec’s product portfolio is a unique and proprietary approach that combines fluorescence microscopy with advanced digital image analysis.⁶ This technology automates and standardizes the process of cell counting. In a typical workflow, a cell sample is mixed with a fluorescent dye that stains the nuclei of the cells. The sample is then loaded into a proprietary disposable cassette, which is inserted into the instrument. The instrument’s optical system captures a digital image, and its software algorithm identifies and counts the fluorescent nuclei, delivering a precise and objective cell count and viability assessment. This method simplifies what can be a complex analytical process, providing what customers regard as “best in class” consistency and accuracy—a critical requirement in both research and regulated manufacturing settings.⁷

1.2 The “Razor-and-Blade” Business Model

ChemoMetec’s commercial success is underpinned by a classic and highly effective “razor-and-blade” business model, which creates a virtuous cycle of initial sales followed by a long-term stream of high-margin, recurring revenue.⁸ This model is comprised of three core revenue streams:

• Instruments (The “Razor”): The initial sale of a cell counting instrument, such as a model from the NucleoCounter® or XcytoMatic® families, establishes ChemoMetec’s footprint within a customer’s laboratory or manufacturing suite. These instrument sales represent the upfront capital investment for the customer. As such, this revenue stream is inherently cyclical and sensitive to customers’ capital expenditure budgets, which are, in turn, heavily influenced by broader macroeconomic conditions and the availability of funding within the biotechnology sector.⁷
• Consumables (The “Blades”): This segment constitutes the highly profitable, recurring revenue engine of the business. For every analysis performed on a ChemoMetec instrument, the customer must use a proprietary, single-use consumable. This category includes specialized cassettes (e.g., Via2-Cassette™), glass counting chambers, reagents, and various test kits.³ The revenue from consumables is directly proportional to the size of the company’s installed instrument base and the operational tempo of its customers. This creates a stable and predictable revenue stream that grows steadily as more instruments are placed in the field, providing a crucial buffer against the volatility of instrument sales.⁷
• Services: Complementing the hardware and consumables, ChemoMetec offers a range of services that enhance customer loyalty and generate additional recurring revenue. This includes annual service and maintenance contracts, instrument validation and qualification services (such as for FDA 21 CFR Part 11 compliance), customer training, and relocation packages.³ As the installed base of instruments expands, so does the opportunity for high-margin service contracts, further strengthening the recurring revenue foundation of the business.

The resilience of this model was put to the test and proven during the challenging market conditions of 2023. As a biotech funding winter took hold, customers curtailed capital spending, leading to a sharp 17% decline in instrument sales for the 2022/23 fiscal year. However, the installed base of customers continued their ongoing research and manufacturing activities, driving an 18% increase in consumable sales and a 39% increase in service revenue. This robust performance in the recurring segments offset the instrument decline, allowing the company to still post 4% total revenue growth for the year.⁷ This period clearly demonstrated that the installed base acts as a powerful revenue and margin stabilizer during cyclical downturns, making the business far more durable than a pure-play capital equipment provider.

1.3 Product Portfolio: The NucleoCounter® and XcytoMatic® Platforms

ChemoMetec’s product strategy centers on providing a focused range of instruments that deliver exceptional performance for their core application.

• NucleoCounter® Family: This is the company’s flagship product line and the foundation of its market leadership. The NucleoCounter® instruments are renowned for their precision, robustness, and simple “load-and-go” operation.⁴ The family includes several key models tailored to different user needs:

• NC-202™: This automated cell counter is a significant workhorse and a major revenue contributor, accounting for approximately 36% of total instrument sales in the first half of the 2024/25 fiscal year.¹² Its consistency and reliability have made it a standard in many cell therapy manufacturing workflows.
• NC-200™, NC-250™, and NC-3000™: This range offers varying levels of automation and analytical capability, from basic cell counting and viability (NC-200™) to more advanced, multi-parameter image cytometry (NC-3000™), catering to a spectrum of research and quality control applications.³
• XcytoMatic® Platform: Launched in the 2023/24 timeframe, the XcytoMatic® line represents the next generation of ChemoMetec’s technology, designed to meet the needs of more advanced, higher-throughput applications.⁷ The initial models, the XcytoMatic® 30 (XM30) and XcytoMatic® 40 (XM40), have gained significant market interest and were key drivers of the instrument sales recovery in 2024, particularly in the North American market.¹⁰

Looking forward, the company is strategically moving up the value chain toward higher levels of automation. The ongoing development of the XcytoMatic® 50 is a clear indicator of this strategy. This new instrument is being designed to analyze samples directly from microplates (e.g., 96-well plates), the standard format for automated, high-throughput screening and analysis.¹² By enabling microplate compatibility, ChemoMetec is targeting customers who are scaling up their processes and require integrated, automated workflows, a move that opens up a more demanding and potentially more lucrative segment of the bioprocessing market.

1.4 Customer Base and Geographic Reach

ChemoMetec’s commercial efforts are highly focused on the most advanced and rapidly growing segments of the life sciences industry.

• Key End Markets: The company organizes its primary market into a core business area designated “LCB,” which stands for Life science research, Cell and gene therapy, and Bioprocessing. This segment is the engine of the company, consistently accounting for 92-93% of total revenue.¹⁰ Within LCB, the cell and gene therapy (CGT) market is the most critical driver. ChemoMetec has established a commanding market position in the development and manufacturing of innovative treatments like CAR-T cell therapies for cancer, where precise cell counting is a mandatory requirement at every step of the process—from initial research and process development through to the final quality control check before a patient is treated.⁷ The company also serves smaller markets in animal semen analysis and quality control for the food and beverage industry.¹⁰
• Geographic Distribution: ChemoMetec is a global company, but its revenue is heavily concentrated in the world’s preeminent biotechnology hub. The company operates direct sales and support organizations in key markets, including the USA, UK, Germany, France, and the Netherlands, while utilizing a network of distributors in other territories.⁷

• USA/Canada: This region is the largest and most strategically important market, consistently generating approximately 58-59% of the company’s total revenue.⁸ The performance of the North American market, especially in instrument sales, serves as a key leading indicator for the company’s overall financial health and is closely tied to the funding environment of the US biotech industry.¹²
• Europe: The second-largest region, contributing around 32% of total revenue.¹³
• Rest of World (RoW): This segment, which includes the fast-growing markets in Asia, accounts for the remaining 10-12% of revenue.⁸

The table below provides a clear, quantitative summary of ChemoMetec’s revenue streams, illustrating the dynamics of its business model and geographic focus during the recent downturn and subsequent recovery.

Table 1: Revenue Breakdown by Segment and Geography (DKK Millions)

	H1 2023/24 (Downturn)	% of Total	H1 2024/25 (Recovery)	% of Total	YoY Growth
By Segment
Instruments	61.8	31.0%	87.5	34.8%	+41.6%
Consumables	89.6	45.0%	105.5	41.9%	+17.7%
Services	46.0	23.1%	56.2	22.4%	+22.2%
Other	1.9	0.9%	2.3	0.9%	+21.1%
Total Revenue	199.3	100.0%	251.5	100.0%	+26.2%
By Geography
USA/Canada	115.4	57.9%	150.1	59.7%	+30.1%
Europe	64.4	32.3%	79.9	31.8%	+24.1%
Rest of World (RoW)	19.5	9.8%	21.5	8.5%	+10.3%
Total Revenue	199.3	100.0%	251.5	100.0%	+26.2%
Source: Compiled from H1 2023/24 and H1 2024/25 Interim Reports 9

II. Industry Landscape: The Cell Analysis Market

2.1 Market Size and Growth Dynamics

ChemoMetec operates within the global cell counting and analysis market, a large and structurally growing segment of the broader life sciences industry. According to various market research reports, the global cell counting market was valued between USD 9.34 billion and USD 11.6 billion in the 2023-2024 timeframe.¹⁵

The industry is supported by strong secular tailwinds, with consensus forecasts projecting a compound annual growth rate (CAGR) in the range of 7.7% to 8.6% over the next five to ten years. This robust growth is expected to propel the market to a total size of between USD 16 billion and USD 22.6 billion by 2029-2034.¹⁵

Geographically, North America stands as the dominant market, a fact that aligns perfectly with ChemoMetec’s own revenue distribution. The region’s leadership is underpinned by a high concentration of major pharmaceutical and biotechnology companies, substantial government and private investment in research and development, and a well-established healthcare infrastructure.¹⁵ While North America remains the largest market, the Asia-Pacific region is widely expected to exhibit the fastest growth rate, driven by increasing healthcare investments and a growing biopharmaceutical industry.¹⁵

2.2 Secular Growth Drivers

The consistent growth of the cell counting market is not a cyclical phenomenon but is instead driven by several powerful, long-term secular trends:

• Expanding Cell-Based Research: At its core, the market is fueled by the ever-increasing volume of scientific research that relies on the analysis of cells. Fields such as cancer research, immunology, stem cell biology, and neurology are fundamental drivers of demand for cell counting instruments and consumables.¹⁵ The rising global incidence of chronic and life-threatening diseases, particularly cancer, creates a continuous imperative for more research, which in turn requires more cell analysis.¹⁶
• The Rise of Biopharmaceuticals and Advanced Therapies: The rapid expansion of the biopharmaceutical industry is arguably the most potent tailwind. The development and manufacturing of biologics, and especially the newer modalities of cell-based therapies (like CAR-T) and gene therapies, are highly dependent on precise and frequent cell counting. These analyses are critical for process monitoring, quality control, and final product release, making cell counters an indispensable tool in modern biomanufacturing.¹⁵
• The Shift to Automation: The industry is undergoing a clear and irreversible shift away from traditional, manual cell counting methods, such as using a hemocytometer and a microscope. These manual techniques are slow, labor-intensive, and notoriously prone to subjective operator error, leading to inconsistent results.¹⁹ Automated systems, like those produced by ChemoMetec, offer a compelling value proposition by providing faster, more accurate, and highly reproducible results, while also freeing up valuable technician time. This trend toward automation and higher data quality is a direct tailwind for automated instrument providers.¹⁹

2.3 Market Segmentation and Competitive Ecosystem

The cell analysis market is diverse, with distinct segments and a varied competitive landscape.

• By Product: The market is broadly divided into Instruments and the associated Consumables. Industry data confirms that the consumables segment is the larger of the two and often exhibits a more stable and rapid growth profile. This is because sales are recurring and are driven by the cumulative installed base of instruments, which grows year after year.¹⁵ This market structure strongly validates the strategic focus of ChemoMetec’s “razor-and-blade” business model.
• By End-User: The primary end-users are academic and research institutes, pharmaceutical and biotechnology companies, and hospitals and diagnostic laboratories.¹⁵ While academic institutions represent the largest number of users, pharmaceutical and biotech companies are a particularly crucial segment due to their larger budgets, their need for regulatory-compliant solutions for manufacturing, and their potential for high-volume consumable usage.¹⁵
• Competitive Landscape: ChemoMetec faces competition from a wide array of companies, which can be grouped into two main categories:

• Diversified Life Sciences Giants: This group includes massive, publicly traded corporations like Thermo Fisher Scientific, Merck KGaA, Danaher (which owns Beckman Coulter Life Sciences), and GE Healthcare. These companies offer vast portfolios of scientific products and services and possess formidable global sales and distribution networks.⁴
• Specialized Technology Players: This group consists of companies that, like ChemoMetec, are focused on specific niches or technologies within cell analysis. This is ChemoMetec’s more direct peer group and includes innovators in areas like high-parameter flow cytometry (e.g., Cytek Biosciences), single-cell genomics (e.g., 10x Genomics), and other automated cell analysis and sorting technologies (e.g., NanoCellect Biomedical, Azenta).²

2.4 Technology and Regulatory Environment

The technological landscape of cell analysis is broad, with different methods suited for different applications. Key technologies include flow cytometry, which excels at high-speed, multi-parameter analysis of individual cells, and image-based cytometry, which is ChemoMetec’s area of expertise.²⁰

For a significant portion of the market, particularly customers involved in the development and manufacturing of therapeutics, the regulatory environment is a defining feature. Compliance with stringent regulations, most notably the U.S. Food and Drug Administration’s (FDA) 21 CFR Part 11, is a critical requirement. This regulation sets the standards for electronic records and electronic signatures, ensuring that data is trustworthy, reliable, and has not been tampered with. Instruments and software that are designed to be “21 CFR Part 11 compliant” offer features like secure, time-stamped audit trails, user access controls, and electronic signatures.¹¹ This compliance is not an optional feature but a prerequisite for use in any GMP-regulated environment. Consequently, it creates a substantial barrier to entry for potential competitors and is a powerful source of competitive differentiation for incumbent, compliant providers like ChemoMetec.

This regulatory hurdle fundamentally shapes ChemoMetec’s market positioning. The company is not merely a “cell counting” instrument provider; it functions as a “process control” and “quality assurance” partner for the biomanufacturing industry. Its success is derived less from offering the most technologically complex instruments—such as the high-parameter flow cytometers used in exploratory research—and more from providing an incredibly reliable, simple, and compliant “answer” that can be validated and permanently integrated into a customer’s official, regulatory-filed manufacturing protocol. This distinction is crucial; in a GMP environment, the primary objective is not discovery but repeatable, documented, and validated process control. Once a process is validated using a specific instrument, the cost, time, and regulatory risk associated with changing that instrument are immense, creating exceptionally high switching costs. This dynamic makes the regulated manufacturing market far “stickier” than the more flexible academic research market.

Furthermore, a commonly cited restraint in the broader cell analysis market is the high initial cost of advanced instrumentation.¹⁵ Complex, multi-laser flow cytometers can cost hundreds of thousands of dollars, posing a significant financial barrier for smaller laboratories or early-stage biotechnology companies. This market dynamic paradoxically works to ChemoMetec’s advantage. Its instruments, while sophisticated, are dedicated to a specific function and are generally more affordable than a high-end, multi-purpose research cytometer. For a capital-constrained startup in the cell therapy space that needs to establish a robust and compliant quality control process, a ChemoMetec instrument that performs its essential task perfectly represents a more logical and financially palatable investment. In this way, the market’s “restraint”—the high cost of complex systems—becomes a competitive tailwind for ChemoMetec’s focused and accessible value proposition.

III. Competitive Position & Differentiation

3.1 Sources of Competitive Advantage

ChemoMetec’s strong market position is built on several interlocking competitive advantages that create a durable moat around its business. These are the primary drivers of its success and high profitability.

• Proprietary Technology and Simplicity of Use: The core of ChemoMetec’s advantage lies in its patented image cytometry technology. The combination of a standardized fluorescent dye, a precision-engineered disposable cassette, and a powerful image analysis algorithm automates and de-skills the cell counting process. This approach is not only highly accurate but, critically, it mitigates the subjective human error and variability that plague traditional manual counting methods.⁴ The resulting “load-and-go” simplicity is a key differentiator, making the instruments accessible to lab technicians without specialized training and ensuring consistent results across different users and sites.
• Data Integrity and GMP Compliance: A crucial advantage in its target market is the platform’s design for use in regulated GMP environments. The instrument software is fully compliant with the FDA’s 21 CFR Part 11 requirements for data integrity, electronic records, and signatures.¹¹ This is a non-negotiable feature for any pharmaceutical or biotech company that intends to use the data for quality control of a therapeutic product or in a regulatory submission. This built-in compliance provides customers with audit-ready data and peace of mind, a value proposition that non-compliant systems cannot offer.
• Installed Base and Recurring Revenue Model: With a large and continuously growing installed base of instruments worldwide, ChemoMetec has created a captive market for its proprietary, high-margin consumables. Each instrument placed acts as an annuity, generating a predictable stream of recurring revenue for years. This recurring revenue provides a stable financial foundation that is far less volatile than the capital-equipment-driven instrument sales, as demonstrated during the 2023 market downturn.⁷

3.2 Market Positioning and Value Proposition

ChemoMetec has strategically positioned itself as the provider of the “gold standard” for robust, compliant, and straightforward cell counting. The company does not attempt to compete head-to-head with manufacturers of highly complex, multi-parameter research instruments. For example, competitors like Cytek Biosciences are leaders in full-spectrum flow cytometry, a powerful technology that allows researchers to analyze dozens of cellular markers simultaneously on a single cell—an ideal tool for deep immunological research and discovery.²⁶

ChemoMetec’s value proposition is fundamentally different. It is not focused on providing the most data points, but on providing the most reliable and defensible answer to a single, critical question: “How many viable cells do I have?” This answer is essential for process control, quality assurance, and product release in a regulated manufacturing setting. ChemoMetec’s instruments are designed to be the simple, validated “black box” that delivers this critical data point with unerring consistency.

This precise positioning allows ChemoMetec to occupy a valuable “sweet spot” in the market. Its automated systems are clearly superior to low-end, error-prone manual methods.¹⁹ At the same time, they are less complex and more cost-effective than high-end, research-grade flow cytometers, which are often “overkill” for a dedicated quality control application.²⁰ This focused strategy allows ChemoMetec to dominate its niche, which larger, more diversified players may not find attractive enough to attack with a similarly dedicated product, while smaller startups face significant hurdles in matching the required regulatory compliance.

3.3 Barriers to Entry and Customer Switching Costs

The durability of ChemoMetec’s competitive position is reinforced by significant barriers that protect its market share and profitability.

• Prohibitively High Switching Costs: This is the company’s most powerful competitive moat. For customers in the pharmaceutical and biotech industries, a cell counter is not just a piece of lab equipment; it is an integral part of a validated manufacturing process that has been approved by regulatory bodies like the FDA. Once a ChemoMetec instrument has been written into a company’s official Standard Operating Procedures (SOPs) and included in a Biologics License Application (BLA), switching to a competitor’s instrument is a monumental undertaking. It would require a complete and costly re-validation of that part of the manufacturing process, potentially involving new comparability studies and amendments to regulatory filings. This process introduces significant risk, cost, and delay, making customers extremely reluctant to switch, even if a competitor offers a lower price.
• Regulatory Hurdles: The requirement for GMP and 21 CFR Part 11 compliance acts as a formidable barrier to entry. Developing the robust, validated software with features like secure audit trails and access controls is a complex and expensive endeavor. New entrants cannot simply build a functional cell counter; they must build a fully compliant system and establish a track record of reliability that can withstand the scrutiny of both customers and regulatory auditors.
• Brand Reputation and Trust: Over more than two decades, ChemoMetec has cultivated a strong brand and a reputation for accuracy, reliability, and excellent customer support.⁴ In an industry where data integrity is paramount, this trust is a significant competitive asset that is difficult for new or unproven players to replicate.

The “blade” in ChemoMetec’s business model—the proprietary consumable cassette—is itself a critical component of this technological moat, not merely a business model choice. The single-use, pre-calibrated design of the cassette is a key technical feature that enhances the system’s value proposition for regulated users. Unlike reusable counting chambers that must be meticulously cleaned and maintained between samples, the disposable cassette eliminates this entire workflow step. This drastically reduces the risk of cross-contamination and removes a significant source of potential process variability. By providing a sealed, sterile, and perfectly standardized measurement environment for every single run, the cassette de-skills the operation and guarantees a level of consistency that is difficult to achieve with other methods. This technical superiority for its intended application is intrinsically linked to the generation of recurring revenue, making the business model and the technological moat one and the same.

IV. Financial Performance and Operational Analysis

4.1 Historical Growth and Profitability

ChemoMetec has a long-term track record of delivering impressive and highly profitable growth. The company’s financial history is characterized by rapid revenue expansion coupled with best-in-class profitability metrics. Over the five-year period leading up to 2024, the company achieved an average annual earnings growth rate of 19.7% and an average annual revenue growth rate of 15.4%.²⁹

This growth has been exceptionally profitable. The company consistently generates net profit margins in the range of 35-40% and a return on equity (ROE) that has exceeded 28-30% in recent periods.²⁹ These figures are indicative of a business with a strong competitive position, significant pricing power, and a highly scalable operating model. The historical financial data presented in the table below provides a clear overview of this powerful long-term performance trajectory.

Table 2: 7-Year Financial Summary (Fiscal Years, DKK Millions)

Fiscal Year (Ending June 30)	2018	2019	2020	2021	2022	2023	2024
Revenue	126.2	175.6	214.2	281.3	427.2	442.3	407.4
Revenue Growth (%)	n/a	39.1%	22.0%	31.3%	51.9%	3.5%	-7.9%
EBITDA	44.5	65.1	92.7	135.8	222.9	251.0	186.2
EBITDA Margin (%)	35.3%	37.1%	43.3%	48.3%	52.2%	56.8%	45.7%
Net Income	30.0	42.1	59.4	88.0	159.2	178.6	136.3
Net Margin (%)	23.8%	24.0%	27.7%	31.3%	37.3%	40.4%	33.5%
EPS (DKK)	2.02	2.53	3.56	5.21	9.38	10.29	7.82
Source: Compiled from historical financial data 8

4.2 Analysis of the Recent Cycle (FY2022-2024)

The period from mid-2022 through mid-2024 provides an excellent case study of the company’s business model performance through a full biotech funding cycle. This period clearly illustrates both the company’s key risk—its sensitivity to customer funding—and its core strength—the resilience of its recurring revenue base.

• The Downturn (FY2023 & H1 FY2024): Beginning in the second half of calendar year 2022, the macroeconomic environment shifted dramatically. Rising interest rates and economic uncertainty led to a significant tightening of capital markets, creating a “funding winter” for the biotechnology sector. ChemoMetec’s customers, many of whom are early-stage, capital-sensitive companies, responded by sharply curtailing their capital expenditures.⁷

• The impact on ChemoMetec’s instrument sales was immediate and severe. After years of rapid growth, instrument sales fell by 17% in fiscal year 2022/23 and then plummeted by 43% year-over-year in the first half of fiscal year 2023/24.⁷ The decline was most acute in the critical USA/Canada market, where instrument sales contracted by 52% during that half-year period.¹³
• However, the stability of the “razor-and-blade” model became evident. Despite the halt in new equipment purchases, existing customers continued their ongoing work, driving continued growth in high-margin consumables and services. This recurring revenue provided a critical cushion, preventing a more catastrophic decline in total revenue.⁷
• The Recovery (H2 FY2024 & H1 FY2025): As capital markets for biotech began to thaw in late 2023 and early 2024, customer investment sentiment improved, and pent-up demand for instruments was unleashed.¹⁰

• The recovery was swift and powerful. In the first quarter of fiscal year 2024/25, total revenue surged by 27% year-over-year, propelled by a 61% rebound in instrument sales.¹⁰
• This momentum continued through the first half of fiscal 2024/25, which saw total revenue grow by 26% and instrument sales increase by 42%.¹² The recovery was once again led by the USA/Canada region, where instrument sales soared by an impressive 88% year-over-year.¹² The successful market introduction of the new XcytoMatic® instruments was a significant contributor to this rebound.¹⁰

This full-cycle performance provides a clear playbook for the company’s financial dynamics. It highlights that while ChemoMetec is a secular growth story tied to the long-term rise of cell therapy, its year-to-year performance is that of a “cyclical grower,” with instrument sales acting as the volatile, high-beta component of the business, and consumables providing a stable, low-beta foundation.

4.3 Operating Leverage and Scalability

ChemoMetec’s business model exhibits extremely powerful operating leverage, a direct result of its high gross margins and scalable production. With gross margins consistently exceeding 90% ³³, a large portion of each incremental dollar of revenue—especially from high-margin consumables—falls directly to the operating profit line.

This dynamic is clearly visible during the business cycle. In the recovery period of H1 2024/25, a 26% increase in revenue translated into a much larger 45% increase in EBITDA, causing the EBITDA margin to expand dramatically from 47% to 54%.¹² Conversely, during the downturn of FY2024, the loss of high-margin instrument sales and the presence of a relatively fixed cost base led to margin contraction, with the EBITDA margin falling to 46% from a peak of 57% in the prior year.⁸ This high degree of operating leverage means that the company’s profitability is highly sensitive to changes in revenue growth, amplifying both gains during upswings and pains during downswings.

4.4 Cash Flow Generation and Balance Sheet

The company is a prolific cash generator with an exceptionally strong and conservative balance sheet. The high-margin business model translates directly into robust operating and free cash flow. This financial strength is a significant strategic asset.

As of the latest available data, ChemoMetec held a net cash position of approximately DKK 257 million, comprised of DKK 265 million in cash and equivalents against only DKK 8 million in debt.³⁰ Key balance sheet metrics underscore its financial fortitude, including a debt-to-equity ratio of just 0.01 and a high solvency ratio.⁸

This pristine balance sheet is not just a sign of prudent financial management; it is a strategic weapon. It provided the company with the resilience to navigate the 2023 downturn without financial stress. More importantly, it enables the company to play offense when others may be on defense. The ability to fund the strategic acquisition of Ovizio entirely from cash on hand is a direct result of this financial strength, allowing ChemoMetec to acquire key technology assets opportunistically during periods of market dislocation without needing to access capital markets or take on debt.

V. Growth Opportunities & Strategic Outlook

5.1 Core Market Penetration

The primary and most significant growth driver for ChemoMetec remains the continued penetration and expansion of its core markets, particularly within the cell and gene therapy (CGT) sector. This growth is expected to be sustainable for several reasons.

• Expansion of the CGT Market: The underlying market for advanced therapies is growing robustly. As more cell and gene therapies progress through clinical trials and gain regulatory approval, the demand for GMP-compliant cell counting escalates. Furthermore, as approved therapies like CAR-T treatments move from being options for late-stage, terminal patients (third-line therapy) to earlier lines of treatment (second-line therapy), the total addressable patient population expands significantly, driving higher production volumes.⁷ Each new therapy that standardizes its manufacturing process on a ChemoMetec platform effectively creates a new, long-term annuity stream of high-margin consumable sales.
• Displacement of Manual Methods: A large, albeit mature, opportunity still exists in displacing legacy manual counting methods in academic and research laboratories. Converting these users to automated systems expands the top of the sales funnel and creates a pipeline of future customers who may later move into regulated development and require GMP-compliant solutions.

5.2 Product Innovation and R&D Pipeline

ChemoMetec is actively investing in research and development to enhance its product portfolio and address the evolving needs of its customers.

• XcytoMatic® Platform Adoption: The successful commercial launch of the new XcytoMatic® 30 and 40 instruments is a key near-term growth catalyst. These next-generation systems are driving the current recovery in instrument sales and are being evaluated by major customers for standardization across their global operations.¹³ Management has indicated that the validation processes at these large customer sites are comprehensive and time-consuming. While this may temper the pace of sales growth in the immediate short term, it also reinforces the strength of the company’s moat; the very fact that validation is so rigorous is what creates the powerful customer lock-in once the process is complete.¹² Each successful validation represents the creation of a secure, multi-year revenue stream.
• Development of the XcytoMatic® 50: The company is strategically developing the XcytoMatic® 50, an instrument designed to handle samples in a microplate format.¹² This is a significant step beyond single-sample analysis, targeting higher-throughput applications common in process development, clone screening, and drug discovery. This new platform will open up new market segments and allow ChemoMetec to serve customers who require greater automation and integration in their workflows.

5.3 Strategic M&A: The Transformative Ovizio Acquisition

In a strategically pivotal move, ChemoMetec acquired the Belgian company Ovizio Imaging Systems in October 2024 for a cash consideration of EUR 2.83 million.¹² This acquisition is not merely a bolt-on but represents a potential transformation of the company’s long-term trajectory.

• Technology and Strategic Rationale: Ovizio has developed and commercialized a cell counter based on holographic microscopy. The critical technological differentiator is that Ovizio’s system is designed to be connected directly to a customer’s bioreactor. This enables continuous, on-line or in-line sampling and analysis of the cell culture during the manufacturing process, without compromising the sterile environment of the bioreactor.³⁴
• Market Impact: This acquisition propels ChemoMetec from its traditional strength in at-line quality control (where a sample is manually removed and taken to a nearby instrument) into the highly strategic and rapidly growing market for Process Analytical Technology (PAT). PAT is a framework strongly encouraged by regulatory agencies like the FDA to build quality into the manufacturing process through real-time monitoring and control. By acquiring Ovizio, ChemoMetec gains a foothold in this next-generation market, allowing it to offer a comprehensive solution to its customers: the Ovizio system for in-process control and monitoring, and the NucleoCounter®/XcytoMatic® systems for final batch release and quality control. This synergistic offering could allow ChemoMetec to “own” the entire cell counting workflow, from inside the bioreactor to the final product, significantly expanding its total addressable market and deepening its competitive moat.

5.4 International Expansion

While North America remains the company’s commercial center of gravity, significant long-term growth opportunities exist in other regions. Deepening market penetration in major European markets and capitalizing on the rapid growth of the biopharmaceutical industry in the Asia-Pacific region, particularly in China, represent substantial avenues for future expansion.¹³

VI. Risk Assessment & Industry Headwinds

6.1 Customer Funding Dependency

The most significant and clearly demonstrated business risk facing ChemoMetec is its direct exposure to the cyclical nature of capital markets funding for the biotechnology industry. This is the company’s primary headwind and a key factor that could impact future performance.

• Cyclicality of Instrument Sales: As the financial performance in 2023 and 2024 unequivocally showed, the company’s instrument sales are highly correlated with the availability of capital for its customer base. When funding is abundant and biotech valuations are high, early-stage companies invest aggressively in building out their labs and manufacturing capabilities, driving strong instrument sales for ChemoMetec. Conversely, when capital markets tighten and funding becomes scarce, these same customers defer capital expenditures, leading to a sharp decline in instrument sales.⁷
• A Leveraged Play on the Biotech Sector: This dynamic makes ChemoMetec a leveraged play on the health of the cell and gene therapy sector. The company’s key risk—biotech funding cyclicality—is inextricably linked to its greatest opportunity. When the sector is performing well and attracting investment, ChemoMetec’s growth is likely to significantly outperform. When the sector is out of favor, the company’s growth will inevitably suffer. This volatility is a fundamental feature of the investment thesis, not a flaw, and requires investors to underwrite this cyclicality and take a long-term view on the underlying growth of the end market.

6.2 Competitive and Technological Threats

While ChemoMetec enjoys a strong moat in its niche, it is not immune to competitive and technological pressures.

• Large, Diversified Competitors: The life sciences tools market is home to several large, well-capitalized companies such as Thermo Fisher Scientific and Merck.⁴ While these giants have not historically focused on ChemoMetec’s specific niche with the same intensity, they possess the R&D budgets, global commercial infrastructure, and brand recognition to become formidable competitors if they were to strategically target the GMP-compliant cell counting market more directly.
• Technological Disruption: The field of cell analysis is characterized by rapid innovation. While ChemoMetec’s image cytometry is currently an excellent fit for its target application, the emergence of a disruptive new technology could pose a threat. This could come in the form of a novel detection method that offers superior accuracy, speed, or a significantly lower cost of ownership, potentially eroding ChemoMetec’s technological edge. The continuous advancement of competing technologies like flow cytometry remains a constant competitive pressure.²⁰

6.3 Operational and Geographic Risks

As a global manufacturing company, ChemoMetec is subject to a range of operational risks.

• Foreign Exchange Exposure: A substantial portion of the company’s revenue (over 58%) is generated in U.S. dollars, while a significant portion of its operating costs are denominated in Danish kroner (DKK). This creates a meaningful exposure to fluctuations in the USD/DKK exchange rate. A weakening of the U.S. dollar relative to the krone has a direct adverse impact on the company’s reported revenue and EBITDA margins.⁸
• Customer Concentration Risk: While not explicitly quantified in the available materials, there is a potential risk of customer concentration. As the cell and gene therapy industry matures, it may consolidate around a smaller number of large pharmaceutical companies and contract development and manufacturing organizations (CDMOs). An over-reliance on a few key customers could increase risk if one of those customers were to switch suppliers or if their therapeutic programs were to fail.
• Supply Chain and Manufacturing Risks: The company is dependent on a stable supply of raw materials and electronic components for the manufacturing of its instruments and consumables. Any significant disruption to its supply chain could impact its ability to meet customer demand and affect its financial results.

VII. Management & Corporate Governance

7.1 Leadership Team and Board Oversight

ChemoMetec is guided by an executive team with deep company-specific experience and a board of directors with a diverse and relevant skill set.

• Executive Management:

• Martin Helbo Behrens, CEO: Mr. Behrens was appointed CEO in March 2024, an internal promotion from his role as COO.³⁸ He is a long-tenured employee who previously served as both COO and CFO of ChemoMetec’s critically important U.S. subsidiary. During his time in the U.S., he was instrumental in driving the company’s high growth and commercial success in its largest market.³⁸ His appointment to the CEO position signals a clear strategic focus on global commercial execution and market penetration, particularly for the new XcytoMatic® product line. It represents a shift toward a leadership profile with a proven track record of driving sales in the company’s most vital region.
• Kim Nicolajsen, CFO: Mr. Nicolajsen serves as the Chief Financial Officer, responsible for the company’s financial management and reporting.⁵
• Board of Directors: The Board of Directors is considered experienced, with an average tenure of 4.3 years.⁴⁰ The composition of the board reflects a deliberate effort to bring together a range of relevant expertise:

• Niels Thestrup (Chairman): An attorney with expertise in commercial law, capital markets, and corporate governance.⁴¹
• Martin Glensbjerg (Deputy Chairman): A co-founder of ChemoMetec, Mr. Glensbjerg provides invaluable long-term institutional knowledge and expertise in product development, production, and business development.⁴¹
• Kristine Færch: A Project Director at the global pharmaceutical leader Novo Nordisk, Ms. Færch brings deep expertise in biology and R&D, as well as an in-depth understanding of the needs and challenges of ChemoMetec’s principal customer group.⁴¹
• The board also includes members with specific expertise in strategic development, digitalization, and sales and marketing.⁴¹

7.2 Capital Allocation Philosophy

ChemoMetec’s management and board have demonstrated a disciplined and value-focused approach to capital allocation.

• Internal Investment (R&D): The company prioritizes internal investment in research and development to drive organic growth. The development and launch of the next-generation XcytoMatic® platform and the ongoing work on the XcytoMatic® 50 are clear evidence of this commitment to product innovation.¹²
• Strategic Mergers & Acquisitions (M&A): Management has shown a willingness to pursue strategic, bolt-on acquisitions to acquire new technologies and expand its market position. The acquisition of Ovizio is a prime example. The all-cash nature of the transaction and its relatively small size compared to ChemoMetec’s balance sheet suggest a prudent and disciplined approach to M&A.³⁴
• Returns to Shareholders: The company has a policy of returning excess capital to shareholders through dividends. The company has paid an annual dividend in recent years, demonstrating a commitment to shareholder returns.⁶

7.3 Corporate Governance Practices

ChemoMetec adheres to the corporate governance standards required for its listing on the Nasdaq Copenhagen exchange. The company publishes annual Corporate Governance and Remuneration reports, providing transparency into its practices.⁴³

The remuneration policy for the executive management team is designed to align their interests with those of shareholders. It includes a variable, cash-based incentive component that is directly tied to the achievement of specific financial performance targets, namely organic revenue growth and EBITDA performance.³¹ The effectiveness of this policy was demonstrated in the challenging 2023/24 fiscal year, when the performance criteria were not met, and as a result, no bonus was awarded to the Executive Management. This indicates that the incentive structure is meaningfully tied to actual business performance.³¹

VIII. Valuation Analysis

8.1 Historical and Current Trading Multiples

ChemoMetec consistently trades at a premium valuation, reflecting its high-quality financial profile and strong growth prospects. An analysis of its current and historical valuation multiples is essential to understanding how the market perceives the company. As of late 2024 and early 2025, the company’s key valuation metrics were in the following ranges:

• Price-to-Earnings (P/E) Ratio (TTM): Approximately 53x to 60x.⁶
• Price-to-Sales (P/S) Ratio (TTM): Approximately 19.5x to 22.3x.²³
• Enterprise Value-to-EBITDA (EV/EBITDA) (TTM): Approximately 40x to 45x.²³

While these multiples have compressed from the speculative peaks reached during the 2021 biotech bull market, they remain elevated both in absolute terms and relative to the broader market. Historical valuation data indicates that the market has long recognized ChemoMetec’s quality and has consistently awarded it a premium multiple.⁴⁷

8.2 Peer Group Benchmarking

When benchmarked against a peer group of other publicly traded companies in the Life Sciences Tools & Services industry, ChemoMetec’s valuation premium becomes starkly apparent. The company’s valuation multiples are significant outliers compared to many of its peers.

The market is clearly pricing ChemoMetec differently from its peers. A simple relative valuation exercise would conclude that the stock is extremely overvalued. However, such an analysis would be incomplete without considering the vast differences in business quality and financial performance.

8.3 Synthesis: Justifying the Premium

The central valuation question for ChemoMetec is whether its substantial premium is justified by its fundamental characteristics.

• The Case for the Premium: The market’s willingness to pay a high multiple for ChemoMetec’s shares is rooted in its demonstrably superior financial profile and business quality. The company’s EBITDA margins, which have exceeded 50%, and its return on equity, often near 30%, are in a different league than most of its peers. These exceptional metrics are the direct result of its strong competitive moat, the high-margin, recurring revenue from its “razor-and-blade” model, and its focused exposure to the secularly growing cell and gene therapy market. The market is essentially paying a premium for a combination of high growth, high profitability, and high predictability.
• The Case for Caution: The premium valuation leaves very little margin for safety. The stock is priced for a high degree of execution excellence. Any significant slowdown in growth, unexpected margin compression, or strategic misstep could lead to a rapid and severe de-rating of its valuation multiple. Furthermore, the company’s inherent cyclicality, as demonstrated in 2023, suggests that paying a peak multiple could be a risky proposition if the biotech funding environment were to deteriorate once again. Indeed, one Discounted Cash Flow (DCF) model analysis suggests that the stock is trading significantly above its intrinsic value based on projected future cash flows.⁴⁶

Ultimately, ChemoMetec should not be valued as a generic company in the “Life Sciences Tools” industry. A more appropriate framework is to view it as a “High-Quality Niche Monopoly.” Its financial characteristics—high recurring revenue, a captive customer base with high switching costs, and dominant market share in its niche—are more analogous to a best-in-class vertical market software company than a typical laboratory equipment manufacturer. The market appears to be pricing the stock based on the superior quality and durability of its earnings stream, not just the absolute magnitude of its revenue or profit.

Table 3: Valuation Peer Group Comparison

Company	Market Cap	EV/Sales (TTM)	P/E (TTM)	EV/EBITDA (TTM)	EBITDA Margin (%)	ROE (%)
ChemoMetec A/S (CHEMM.CO)	~1.42B USD	~21.7x	~60.5x	~45.3x	~48%	~30.8%
Azenta, Inc. (AZTA)	~1.47B USD	~1.5x	NM	~35.7x	~4%	NM
Evotec SE (EVO)	~1.53B USD	~1.9x	NM	~1,313x	~0.1%	NM
10x Genomics, Inc. (TXG)	~1.53B USD	~1.9x	NM	NM	Negative	NM
AbCellera Biologics Inc. (ABCL)	~1.16B USD	~27.1x	NM	NM	Negative	NM
Note: All figures are approximate and based on data from late 2024/early 2025. USD equivalents are for comparison. NM = Not Meaningful (typically due to negative earnings). EBITDA Margin calculated as EBITDA/Revenue. Source: Compiled from 23

IX. Concluding Analysis: Key Catalysts and Investment Considerations

9.1 Potential Catalysts for Outperformance

Several key factors could drive ChemoMetec’s financial performance and stock price to exceed current expectations.

• A Sustained Biotech Funding Recovery: The most powerful near-term catalyst would be the continuation and acceleration of the recovery in the biotech capital markets. A strong funding environment would directly translate into higher capital expenditures from ChemoMetec’s customer base, driving instrument sales growth beyond current forecasts and leading to significant positive operating leverage and earnings beats.
• Major Customer Standardization on XcytoMatic®: A public announcement that one or more major pharmaceutical companies or leading CDMOs have selected the new XcytoMatic® platform as their global standard for cell counting in a commercial therapy would be a major validation event. Such a development would not only secure a large, long-term stream of high-margin consumable revenue but would also likely trigger follow-on adoption by other players in the industry.
• Successful Commercialization of Ovizio Technology: Early evidence of successful integration and commercial traction with the newly acquired in-line PAT technology from Ovizio could be a transformative catalyst. If ChemoMetec can successfully leverage this technology to win new customers in the bioprocessing space, the market may be compelled to re-evaluate the company’s total addressable market and assign it a higher long-term growth rate.

9.2 Potential Catalysts for Underperformance

Conversely, several risks could lead to the company’s performance falling short of expectations, potentially resulting in a contraction of its premium valuation multiple.

• A Renewed Downturn in Biotech Funding: Given the demonstrated sensitivity of instrument sales to the biotech funding cycle, a reversal of the recent market recovery would pose the most significant threat. A new “biotech winter” would almost certainly lead to a repeat of the 2023 slowdown, pressuring revenue and margins and likely causing a de-rating of the stock.
• Execution and Integration Risks: The company’s growth outlook is dependent on successful execution. Any significant delays in the broader rollout of the XcytoMatic® platform, or any unforeseen challenges in integrating and commercializing the Ovizio technology, could lead to a shortfall in growth and disappoint investor expectations.
• Increased Competitive Intensity: While the company’s moat is strong, it is not impenetrable. The launch of a “good enough,” GMP-compliant, and significantly lower-priced cell counting solution by a major, well-capitalized competitor could introduce pricing pressure and threaten ChemoMetec’s market share in its core segments.

9.3 Final Synthesis

ChemoMetec represents a compelling case of a best-in-class operator that has achieved a dominant position in a highly attractive and structurally growing niche market. The company possesses a formidable competitive moat, anchored by extremely high customer switching costs in regulated environments. This moat protects a business model that generates exceptional profitability, high returns on capital, and strong, recurring cash flows.

However, the company’s fortunes are inextricably linked to the health and funding environment of the volatile biotechnology sector, which introduces a significant element of cyclicality to its growth trajectory. This inherent cyclicality, combined with a valuation that consistently trades at a substantial premium to its peers, creates a challenging dynamic for prospective investors.

The investment decision ultimately hinges on a careful weighing of these factors. It requires a long-term conviction in the continued growth of the cell and gene therapy industry, a tolerance for the inevitable volatility driven by the biotech funding cycle, and a fundamental judgment on whether the company’s undeniably superior quality and strategic positioning justify its premium price. The recent strategic acquisition of Ovizio adds a new, potentially transformative dimension to the growth story, offering an upside catalyst that may not yet be fully reflected in the market’s valuation.

Works cited

1. Investor Relations – Chemometec, accessed August 29, 2025, https://investor.chemometec.com/
2. ChemoMetec – 2025 Company Profile, Funding & Competitors – Tracxn, accessed August 29, 2025, https://tracxn.com/d/companies/chemometec/__UeC51G1OBLS9Z8wR2Lq6JVzsmRp1kQ6H60bhMcjIx6c
3. ChemoMetec (CPH:CHEMM) Company Profile & Description – Stock Analysis, accessed August 29, 2025, https://stockanalysis.com/quote/cph/CHEMM/company/
4. ChemoMetec (CHEMM) Investor Relations Material – Quartr, accessed August 29, 2025, https://quartr.com/companies/chemometec_4851
5. CHEMM Investor Relations – Chemometec A/S – Alpha Spread, accessed August 29, 2025, https://www.alphaspread.com/security/cse/chemm/investor-relations
6. Chemometec A/S, CHEMM:CPH summary – FT.com – Markets data, accessed August 29, 2025, https://markets.ft.com/data/equities/tearsheet/summary?s=CHEMM:CPH
7. Annual Report 2022/23 | ChemoMetec, accessed August 29, 2025, https://chemometec.com/wp-content/uploads/2023/09/ChemoMetec_Annual-Report-2022-23_UK.pdf
8. ChemoMetec A/S, accessed August 29, 2025, https://investor.chemometec.com/static-files/837a64fe-a778-4209-9239-313d77a3aa0f
9. Interim report, accessed August 29, 2025, https://ml-eu.globenewswire.com/Resource/Download/8c81130a-423b-421e-bb59-ab60def478c6
10. Growth in revenue and operating profit – Investor Relations – Chemometec, accessed August 29, 2025, https://investor.chemometec.com/static-files/124b0c4f-3586-47a2-a0ce-0e1d6f5a339c
11. Publications Review – ChemoMetec, accessed August 29, 2025, https://chemometec.com/publications-review/
12. Solid H1 performance driven by growth in both revenue and earnings – Investor Relations – Chemometec, accessed August 29, 2025, https://investor.chemometec.com/static-files/7ccaf233-6a76-40c3-acbb-625831967c2c
13. Interim report – Investor Relations – Chemometec, accessed August 29, 2025, https://investor.chemometec.com/static-files/8ba95d55-c0cc-44ff-94bb-e982f1f191cc
14. Growth in revenue and operating profit – GlobeNewswire, accessed August 29, 2025, https://www.globenewswire.com/news-release/2024/11/07/2976926/0/en/Growth-in-revenue-and-operating-profit.html
15. Cell Counting Market Size & Growth Forecast to 2029, accessed August 29, 2025, https://www.marketsandmarkets.com/Market-Reports/cell-counting-market-157450728.html
16. Cell Counting Market Size, Share & Trends | Industry Report, 2033 – Straits Research, accessed August 29, 2025, https://straitsresearch.com/report/cell-counting-market
17. Cell Counting Market Size – Trends Analysis Report, 2032, accessed August 29, 2025, https://www.gminsights.com/industry-analysis/cell-counting-market
18. Cell Counting Market Size to Surpass USD 22.60 Billion by 2034 – Precedence Research, accessed August 29, 2025, https://www.precedenceresearch.com/cell-counting-market
19. Cell Counting Market Size Grows at 8.41% CAGR by 2034 – Towards Healthcare, accessed August 29, 2025, https://www.towardshealthcare.com/insights/cell-counting-market-sizing
20. Cell Analysis Instruments Market Size Projected to Grow at a CAGR of 10% by 2032, accessed August 29, 2025, https://straitsresearch.com/report/cell-analysis-instruments-market
21. ChemoMetec Company Overview, Contact Details & Competitors | LeadIQ, accessed August 29, 2025, https://leadiq.com/c/chemometec/5a1d8ad62400002400652f9d
22. ChemoMetec 2025 Company Profile: Stock Performance & Earnings – PitchBook, accessed August 29, 2025, https://pitchbook.com/profiles/company/151899-49
23. ChemoMetec A/S (CHHMF) Stock Competitors & Similar Stocks …, accessed August 29, 2025, https://seekingalpha.com/symbol/CHHMF/peers/comparison
24. Cell Analysis Market Size & Share | Industry Report, 2030 – Grand View Research, accessed August 29, 2025, https://www.grandviewresearch.com/industry-analysis/cell-analysis-market-report
25. Cell Analysis Market Growth, Drivers, and Opportunities – MarketsandMarkets, accessed August 29, 2025, https://www.marketsandmarkets.com/Market-Reports/cell-analysis-market-157543946.html
26. Cytek Biosciences – All Products | DKSH Technology, accessed August 29, 2025, https://technology-products.dksh.ph/brand/cytek-biosciences/
27. Cytek Biosciences – All Products | DKSH Technology, accessed August 29, 2025, https://technology-products.dksh.id/id-en/brand/cytek-biosciences/
28. Cytek Biosciences: Full Spectrum Flow Cytometry Systems | Discover the Advantages, accessed August 29, 2025, https://cytekbio.com/
29. ChemoMetec (CPSE:CHEMM) – Earnings & Revenue Performance …, accessed August 29, 2025, https://simplywall.st/stocks/dk/pharmaceuticals-biotech/cph-chemm/chemometec-shares/past
30. ChemoMetec (CPH:CHEMM) Statistics & Valuation Metrics – Stock Analysis, accessed August 29, 2025, https://stockanalysis.com/quote/cph/CHEMM/statistics/
31. Remuneration Report 2023/24 – Investor Relations – Chemometec, accessed August 29, 2025, https://investor.chemometec.com/static-files/439382e8-7ef7-4255-956f-b94dfb0f626c
32. Interim report – Investor Relations – Chemometec, accessed August 29, 2025, https://investor.chemometec.com/static-files/3bed46ab-6da7-4e93-b80a-7740116d5602
33. ChemoMetec Stock Price Today | CSE: CHEMM Live – Investing.com, accessed August 29, 2025, https://www.investing.com/equities/chemometec
34. Acquisition of Ovizio Imaging Systems SA – GlobeNewswire, accessed August 29, 2025, https://www.globenewswire.com/news-release/2024/10/16/2964249/0/en/Acquisition-of-Ovizio-Imaging-Systems-SA.html
35. Closing of acquisition of Ovizio Imaging Systems SA – GlobeNewswire, accessed August 29, 2025, https://www.globenewswire.com/news-release/2024/10/22/2967166/0/en/Closing-of-acquisition-of-Ovizio-Imaging-Systems-SA.html
36. ChemoMetec Completes Acquisition of Ovizio Imaging Systems SA: Enhancing Bioprocessing and Cell Therapy Capabilities – AInvest, accessed August 29, 2025, https://www.ainvest.com/news/chemometec-completes-acquisition-of-ovizio-imaging-systems-sa-enhancing-bioprocessing-and-cell-therapy-capabilities-241010109eb1038483f29592/
37. ChemoMetec makes offer to buy Ovizio Imaging Systems SA – BioSpace, accessed August 29, 2025, https://www.biospace.com/press-releases/chemometec-makes-offer-to-buy-ovizio-imaging-systems-sa
38. Appointment of new CEO – GlobeNewswire, accessed August 29, 2025, https://www.globenewswire.com/news-release/2024/03/13/2845202/0/en/Appointment-of-new-CEO.html
39. Executive Leadership Team – Investor Relations – Chemometec, accessed August 29, 2025, https://investor.chemometec.com/corporate-governance/executive-leadership-team/
40. ChemoMetec A/S (CHEMM) Leadership & Management Team Analysis – Simply Wall St, accessed August 29, 2025, https://simplywall.st/stocks/dk/pharmaceuticals-biotech/cph-chemm/chemometec-shares/management
41. Board of Directors – Investor Relations – Chemometec, accessed August 29, 2025, https://chemometec.gcs-web.com/corporate-governance/board-of-directors
42. ChemoMetec (CPSE:CHEMM) – Stock Analysis – Simply Wall St, accessed August 29, 2025, https://simplywall.st/stocks/dk/pharmaceuticals-biotech/cph-chemm/chemometec-shares
43. Corporate Governance Reports – Investor Relations – Chemometec, accessed August 29, 2025, https://investor.chemometec.com/corporate-governance/corp-gov-reports/
44. Corporate Governance at ChemoMetec – Investor Relations …, accessed August 29, 2025, https://investor.chemometec.com/static-files/9fbb02cb-018b-41e7-b836-b75506b40407
45. Remuneration Reports – Investor Relations – Chemometec, accessed August 29, 2025, https://investor.chemometec.com/corporate-governance/remuneration-reports/
46. ChemoMetec (CPSE:CHEMM) Stock Valuation, Peer Comparison & Price Targets, accessed August 29, 2025, https://simplywall.st/stocks/dk/pharmaceuticals-biotech/cph-chemm/chemometec-shares/valuation
47. CHEMM Relative Valuation – Chemometec A/S – Alpha Spread, accessed August 29, 2025, https://www.alphaspread.com/security/cse/chemm/relative-valuation